Background. Both IL-9 and miR-200a are involved in the pathogenesis of cancers; however, the role of IL-9 in pancreatic cancer and the possible underlying mechanisms remain unknown. The aim of this study was to investigate the effect of IL-9 on pancreatic cancer cells and its interaction with miR-200a. 
Introduction
Pancreatic cancer is a highly lethal malignancy and the fourth most common cause of cancer deaths worldwide. The prognosis of pancreatic cancer remains quite poor, with overall 5-year survival rates of <5%, mostly due to local recurrence and metastasis [1] . Though great progress has been made over the past few decades, the pathogenesis of pancreatic cancers remains largely unknown, especially the mechanism underlying cancer metastasis. miR-200a expression has been reported to be downregulated during the progression of many cancers. miR-200a is able to suppress the epithelialmesenchymal transition (EMT) process [2] [3] [4] , which is a critical step in cancer metastasis initiation. In addition, miR200a has also been shown to suppress cell proliferation and metastasis in several cancers such as pancreatic cancer [5] and hepatocellular carcinoma [6] . More recently, Wu et al. reported that miR-200a suppresses pancreatic cancer cell metastasis via the downregulation of DEK, suggesting that miR-200a may constitute a novel target for pancreatic cancer treatment [7] .
IL-9 is a multifunctional cytokine secreted by activated Th2 cells, Th9 cells, and regulatory T-cells [8] . The targets of IL-9 include mast cells, T-cell clones, and B-lymphocytes [8] , through which IL-9 plays a crucial role in immune reactions against parasites [9] , asthma [10] , and lymphoma [11] development. In addition to its role in immune and inflammatory diseases, emerging evidence indicates that IL-9 participates in the pathogenesis of cancers, acting mostly as a cancer development promoting factor, especially in nonsolid tumors [12] [13] [14] . The interaction between cytokines and miRNAs during tumorigenesis is receiving increasing attention; examining this interaction is critical to uncovering the mechanisms underlying tumorigenesis. Therefore, this study aimed to investigate the role of the interaction between IL-9 and miR-200a in the modulation of pancreatic cancer progression in order to elucidate the underlying molecular mechanisms.
Materials and Methods

Cell Culturing.
Two pancreatic cancer cell lines (PANC-1 and AsPC-1 cells) and one normal pancreatic cell line (HPDE6-C7) were purchased from the ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL Co. Ltd., USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, and 100 mg/ml streptomycin. Culture medium was replaced every 24 h unless otherwise stated and cells were incubated at 37 ∘ C with 5% CO 2 .
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR).
Total RNA plus miRNAs were isolated from cultured cells or tissue using the mirVana miRNA isolation kit (TaKaRa, Dalian, China), reverse transcribed, and then subjected to SYBR Green-based RT-PCR analysis (TaKaRa).
qRT-PCR assays for miR-200a and -catenin were performed using the PrimeScript RT Reagent Kit (TaKaRa), SYBR Green miRcute miRNA Real-Time PCR Kit (QIAGEN, Hilden, Germany), SYBR Green Real-Time PCR Master Mix, and Premix Ex Taq (TaKaRa) according to the manufacturers' protocols.
The assays were performed with the following primers: miR-200a 5 -CGT AAC ACT GTC TGG TAA CGA TGT-3 ; U6 5 -CGC AAG GAT GAC ACG CAA ATT CGT-3 ; -catenin forward 5 -GAA ACG GCT TTC AGT TGA GC-3  and reverse 5 -CTG GCC ATA TCC ACC AGA GT-3 ; and  GAPDH forward 5 -CGG ATT TGG TCG TAT TG-3 and  reverse 5 -GAA GAT GGT GAT GGG ATT-3. These primers were purchased from Sangon Biotech (Shanghai, China). miR-200a level was normalized to U6, and -catenin level was normalized to GAPDH. Gene expression was analyzed using the 2 −ΔΔCT method. At least three independent experiments were conducted for each experimental condition.
Western-Blot Analysis.
Protein was collected from 2 × 10 6 cells treated with IL-9 for 48 h using a lysis buffer containing protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Cell lysates were centrifuged at 14,000 rpm at 4 ∘ C for 15 min. Protein samples were mixed with 5x sample buffer (4 : 1 ratio) and heated at 95 ∘ C for 10 min and then separated on 10% sodium dodecyl sulfate-polyacrylamide gels. Following electrophoresis for 90 min, the proteins were transferred onto a polyvinylidene fluoride membrane (Merck Millipore, Billerica, MA, USA). The membranes were blocked for 1 h at room temperature with 5% nonfat milk in 0.1% TBS-Tween 20 and then incubated with anti--catenin (1 : 2000 dilution; Abcam, Cambridge, MA, USA) at 4 ∘ C overnight, followed by incubation with LI-COR IRDye 680-labeled secondary antibodies (Rockland Immunochemicals, Gilbertsville, PA, USA) for 1 h at room temperature. Signals were detected with an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA) and quantitated using the FluorChem 8900 system (Alpha Innotech, San Leandro, CA, USA). No vehicle control was used.
Cell Proliferation
Cell Apoptosis Analysis.
The preparation of cell apoptosis was similar to the cell proliferation assay. Quantification of apoptotic cells was performed using the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, Vienna, Austria) according to the manufacturer's instructions. Analyses were conducted with a BD FACSCalibur flow cytometer (BD Biosciences); apoptotic cells were defined as Annexin V-positive cells. Three independent experiments were performed.
In Vitro Migration and Invasion Assays.
Cell migration and invasion abilities were tested using the Transwell assay. Comparisons of multiple groups were analyzed using oneway analysis of variance (ANOVA) followed by the LSD post hoc test. Differences were considered to be statistically significant at < 0.05. 
Results
IL-9 Promotes Pancreatic Cancer Cell Proliferation and
miR-200a Inhibits Pancreatic Cancer Cell Proliferation and
Discussion
In the present study, we show that IL-9 promotes pancreatic cancer cell proliferation and metastasis and that this effect might occur via the miR-200a/ -catenin axis. In addition, we also observed that IL-9 has a little effect on pancreatic cancer cell apoptosis. In line with a previous study [15] , we found The molecular mechanism underlying pancreatic cancer is complex; several studies have demonstrated that both traditional genes and miRNAs contribute to tumorigenesis in the pancreas. Several miRNAs have been found to be associated with the development and progression of pancreatic cancer. Of these, miR-200a has been shown to be a critical factor able to suppress proliferation and metastasis of some cancers including non-small-cell lung cancer [17] , pancreatic cancer [5] , and hepatocellular carcinoma [6] . A recent study has identified -catenin as a direct target of miR-200a and that overexpression of M2-type pyruvate kinase negatively regulates -catenin through miR-200a in colon cancer cells [16] . Another study found that downregulation of miR-200a can induce EMT phenotypes and CSC-like signatures by targeting the -catenin pathway in hepatic oval cells [18] . These studies indicate that the miR-200a/ -catenin axis may be involved in the proliferation and metastasis of several cell types.
IL-9 has been implicated in a number of immune or inflammatory diseases such as parasitic infection, allergy, and asthma disease [9] [10] [11] ; however, the function of IL-9 in tumor immunity remains unclear and controversial The invasion and migration rate of PANC-1 and AsPC-1 cells was increased after IL-9 treatment using Transwell assay. Data was expressed as mean ± SD. * < 0.05. * * < 0.01. [19, 20] . Huang et al. [21] reported that IL-9 expression was decreased in the tissue and plasma samples of colon cancer patients and that the decreased expression of IL-9 was correlated with colon cancer progression. However, Hoelzinger et al. [22] showed that eliminating endogenous IL-9 enabled sensitization of host T-cells to tumors, leading to their early rejection without the requirement of vaccines or immunomodulatory therapies. These discrepancies may be partly explained by the timing of IL-9 secretion in a given pathologic circumstance and by the different cell types (such as Th17 and Th9 cells) that express the IL-9 receptor [22] ; a number of studies have shown that IL-9 secreted by Th17 or Th9 cells has an opposite effect on experimental autoimmune encephalitis [23, 24] . In this study, we observed that IL-9 was able to promote the proliferation, invasion, and migration of pancreatic cancer cells in a concentration-dependent manner and the miR-200a expression was lower in pancreatic cancer cells than normal pancreatic cells, suggesting that IL-9 has tumorpromoting activities in pancreatic cancer. Thus, anti-IL-9 could be used as a novel potential approach in the treatment of pancreatic cancer metastasis. In addition, we examined the interaction of IL-9 and miR-200a in PANC-1 cells. The results showed that the effect of inhibition of miR-200a on pancreatic cancer cells was promoted following IL-9 treatment. Moreover, IL-9 decreased miR-200a expression and increasedcatenin expression even following miR-200a mimics infection, suggesting that the effect of IL-9 on pancreatic cancer cells may occur through the miR-200a/ -catenin axis.
A number of study limitations need to be noted. First, only the PANC-1 and AsPC-1 cells lines were used to explore the effect of IL-9 on pancreatic cancer cells and was overexpressed in most of our study using miR-200a mimics, but knockdown/knockout miR-200a in pancreatic cells can make the results more reliable. Therefore, future studies should address and resolve these limitations.
In conclusion, our study demonstrates that IL-9 promotes proliferation and metastasis in pancreatic cancer cells and that this effect may occur via regulation of the miR-200a/ -catenin axis, suggesting that both IL-9 and miR-200a could be used as potential biomarkers in the treatment of pancreatic cancer. 
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